Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-08-01
2010-06-22
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100, C514S002600, C514S012200, C530S350000, C435S252700
Reexamination Certificate
active
07740868
ABSTRACT:
Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 2006/0024331 (2006-02-01), Fernandez-Salas et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: EP 0359347 (1990-03-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 99/55359 (1999-11-01), None
patent: WO01-14570 (2001-03-01), None
patent: WO2004-024909 (2004-03-01), None
Tonello et al, “Tetanus and Botulinum Neurotoxins a Novel Group of Zinc-Endopeptidases”, Intracellular Protein Catabolism, Adv. Exp. Med. & Biol. 389, pp. 251-260 (1996).
Li, Yan et al., “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain”,Biochemistry(1994), 33(22), 7014-20 CODEN: Bichaw; Issn: 0006-2960: pp. 7014-7020.
Coffield et al., “The Site and Mechanism of Action of Botulinum Neurotoxin”,Neurological Disease and Therapy, pp. 3-13, 25 (Jankovic J. & Hallett M. eds. 1994).
Foran et al, “Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine Release”, Biochem. 35: pp. 2630-2636 (1996).
Dolly et al, “Probing the process of transmitter release with botulinum and tetanus neurotoxins” Seminars in Neuroscience, 6(3): pp. 149-158 (1994).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxiicity after Reconstruction with the Heavy Chain”, Biochemistry 34: pp. 15175-15181 (1995).
Lacy et al, “Crystal structure of botulinum neurotoxin type A and implications for toxicity” Nature Struct. Biol. Oct; 5 (10): pp. 898-902 (1998).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Cahins of Tetanus Toxin and Botulinum Neurotoxin Type A”, J. Biol. Chem.: pp. 14721-14729 (1992), Hutchison et al.
“Mutagenesis at a Specific Position in a DNA Sequence”, J. Biol. Chem. 253: No. 18, Sep. 25 issue, pp. 6651-6560 (1978).
Li et al, “Expression and Characterization of the Heavy Chain of Tetanus Toxin: Reconstruction of the Fully-Recombinant Dichain Proetin in Active Form”, J. Biochem. 125: pp. 1200-1208 (1999).
U.S. Appl. No. 60/150,710, filed Aug. 25, 1999, Dolly et al.
U.S. Appl. No. 11/610,440, filed Dec. 13, 2006, Dolly et al.
U.S. Appl. No. 11/781,359, filed Jul. 23, 2007, Dolly et al.
U.S. Appl. No. 11/782,112, filed Jul. 24, 2007, Dolly et al.
U.S. Appl. No. 11/832,108, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/845,167, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/829,475, filed Jul. 27, 2007, Steward et al.
U.S. Appl. No. 11/833,142, filed Aug. 2, 2007, Steward et al.
U.S. Appl. No. 11/833,720, filed Aug. 3, 2007, Steward et al.
U.S. Appl. No. 11/834,068, filed Aug. 6, 2007, Steward et al.
U.S. Appl. No. 11/844,780, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,850, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,885, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,929, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,919, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,899, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,517, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,546, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/845,252, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,284, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,320, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,345, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,466, filed Aug. 27, 2007, Steward et al.
Abdel-Malek, “Melanocortin receptors: their functions and regulation by physiological agonists and antagonists”, Cell. Mol. Life Sci. 58, 434-441, 2001.
Catania et al, “Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation”, Pharmacol Rev. 56: 1-29, 2004.
Gantz et al, “The melanocortin system”, Am J Physiol Metab, 284: E468-E474, 2003.
Gantz et al, “Molecular Cloning, Expression, and Characterization of a Fifth Melanocortin Receptor”, vol. 200, 1214-1220, 1994.
Starowicz et al, “The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception”, Life Sciences 73, 823-847, 2003.
Aoki Kei Roger
Dolly J. Oliver
Fernandez-Salas Ester
Francis Joseph
Ghanshani Sanjiv
Allergan Inc.
Allergan, Inc.
German Joel B.
Kam Chih-Min
Stathakis Dean G.
LandOfFree
Activatable clostridial toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activatable clostridial toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activatable clostridial toxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167163